BioLife Solutions, Inc.
$22.19
▲
1.14%
2026-04-21 05:42:00
www.biolifesolutions.com
NCM: BLFS
Explore BioLife Solutions, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.04 B
Current Price
$22.19
52W High / Low
$29.62 / $17.86
Stock P/E
—
Book Value
$7.72
Dividend Yield
—
ROCE
-4.34%
ROE
-3.37%
Face Value
—
EPS
$-0.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
155
Beta
2
Debt / Equity
4.81
Current Ratio
5.94
Quick Ratio
4.63
Forward P/E
68.07
Price / Sales
9.91
Enterprise Value
$882.41 M
EV / EBITDA
244.71
EV / Revenue
9.17
Rating
None
Target Price
$32.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Embecta Corp. | $9.6 | 4.08 | $568.51 M | 6.25% | 35.74% | -13.73% | $15.55 / $8.47 | $-10.35 |
| 2. | Envista Holdings Corporation | $27.85 | 97.1 | $4.56 B | — | 4.89% | 1.56% | $30.42 / $14.72 | $18.96 |
| 3. | AptarGroup, Inc. | $125.33 | 21.29 | $8.05 B | 1.47% | 12.5% | 15.1% | $164.28 / $103.23 | $41.56 |
| 4. | Bionano Genomics, Inc. | $1.31 | — | $14.53 M | — | -65.83% | -66.15% | $5.5 / $1.06 | $4.14 |
| 5. | Regentis Biomaterials Ltd. | $2.96 | — | — | — | -181.68% | 75.07% | $8.35 / $2.8 | $0.92 |
| 6. | Hologic, Inc. | NOT FOUND | — | — | — | 9.77% | 10.86% | $76.07 / $51.9 | $23.51 |
| 7. | Baxter International Inc. | $18.8 | — | $9.79 B | 0.21% | 1.04% | -13.71% | $32.68 / $15.73 | $11.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 18.79 M | 28.07 M | 25.42 M | 23.94 M | -3.42 M | — |
| Operating Profit | 1.35 M | -0.09 M | -16.64 M | -1.22 M | 1.39 M | — |
| Net Profit | 11.07 M | 0.62 M | -15.84 M | -0.45 M | 12.46 M | — |
| EPS in Rs | 0.23 | 0.01 | -0.33 | -0.01 | 0.26 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 96.21 M | 74.65 M | 68.02 M | 76.24 M |
| Operating Profit | -16.6 M | -4.48 M | -19.4 M | -10.68 M |
| Net Profit | -4.59 M | -20.18 M | -68 M | -139.81 M |
| EPS in Rs | -0.1 | -0.42 | -1.41 | -2.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 405.88 M | 399.49 M | 412.71 M | 450.23 M |
| Total Liabilities | 34 M | 50.58 M | 75.05 M | 86.04 M |
| Equity | 371.89 M | 348.91 M | 337.66 M | 364.19 M |
| Current Assets | 136.56 M | 148.76 M | 120.6 M | 138.45 M |
| Current Liabilities | 22.98 M | 32.73 M | 42.18 M | 44.58 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 20.11 M | 8.43 M | -12.5 M | -8.49 M |
| Investing CF | -71.54 M | 58.3 M | 17.84 M | -58.12 M |
| Financing CF | -10.92 M | -6.78 M | 10.59 M | 16.32 M |
| Free CF | 0.42 M | 4.9 M | -18.88 M | -18.87 M |
| Capex | -19.7 M | -3.53 M | -6.38 M | -10.38 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.75% | -10.79% | — | — |
| Earnings Growth % | 70.32% | 51.36% | — | — |
| Profit Margin % | -27.04% | -99.98% | -183.38% | — |
| Operating Margin % | -6% | -28.52% | -14% | — |
| Gross Margin % | 67.11% | 60.75% | 61.53% | — |
| EBITDA Margin % | 5.61% | -10.44% | 7.6% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.